Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PLN-101095 |
Synonyms | |
Therapy Description |
PLN-101095 inhibits ITGB8 (integrin alphaVbeta8) and ITGB1 (integrin alphaVbeta1), which potentially results in decreased tumor growth (Journal for ImmunoTherapy of Cancer 2023;11, Suppl 1). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PLN-101095 | PLN101095|PLN 101095 | PLN-101095 inhibits ITGB8 (integrin alphaVbeta8) and ITGB1 (integrin alphaVbeta1), which potentially results in decreased tumor growth (Journal for ImmunoTherapy of Cancer 2023;11, Suppl 1). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06270706 | Phase I | Pembrolizumab + PLN-101095 PLN-101095 | A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |